In an NB setting, preliminary indication of efficacy was observed after exposure of several NB cell lines, including CLB-BAR (MYCN amplification, ALK (Δ4-11) and amplified, ALK addicted), CLB-GE (MYCN amplification, ALK (F1174V) amplification, ALK addicted), IMR32 (MYCN amplification, WT ALK) and CLB-PE (MYCN amplified, WT ALK), in which treatment inhibited cell growth and ALK phosphorylation in a dose-dependent manner. Here, ALK is linked to neuroblastoma.